The Science Behind Stress Supplements

Therapeutic dose: 300–600 mg/day standardized extract (≥5% withanolides)

• 2022 meta-analysis of 12 RCTs (1,002 participants) found ashwagandha significantly reduced anxiety (SMD: -1.55, p=0.005) and stress (SMD: -1.75, p=0.005).
• 2024 meta-analysis of 9 RCTs (558 participants) reduced PSS (MD=-4.72), HAM-A (MD=-2.19), and serum cortisol (MD=-2.58), all p<0.05.
• 2025 meta-analysis of 15 RCTs (873 participants) confirmed significant reductions in cortisol, PSS, and HAM-A scales.
• 2025 BJPsych Open systematic review confirmed benefits for anxiety, depression, sleep, and stress. Optimal forms: KSM-66 or Sensoril (most studied).
• Mechanism: reduces cortisol via HPA axis modulation with additional GABAergic activity and anti-inflammatory effects. Full benefits at 6–8 weeks; some effects at 2–4 weeks.

Therapeutic dose: 80–160 mg/day Silexan

• 2023 meta-analysis of 5 RCTs (1,213 participants) found 80 mg/day significantly superior to placebo (HAMA MD: 2.93, p<0.001) after 10 weeks.
• 2019 network meta-analysis found 80 mg comparable to paroxetine 20 mg. At 160 mg, Silexan was superior to all comparators.
• GAD trial (539 adults, 10 weeks): 160 mg achieved ≥50% HAMA reduction in 60.3% of participants vs 37.8% placebo.
• 18-month safety data showed favorable profile with fewer side effects than lorazepam and no dependence. Included in German anxiety guidelines.
• Key limitation: nearly all trials by manufacturer in Germany; limited independent replication. Generic lavender oil is NOT equivalent to Silexan.

Therapeutic dose: 200–400 mg/day (do NOT exceed 655 mg)

• 2025 meta-analysis of 18 RCTs (897 participants) found improved sleep quality (SMD=0.43, p=0.03) and daytime dysfunction (SMD=0.33, p<0.001). Objective measures (actigraphy, PSG) did not improve.
• 2024 RCT (200 mg/day, 4 weeks) reduced stress (SDS), trait anxiety (STAI), sleep disturbance (PSQI), and improved verbal fluency.
• AlphaWave single-dose RCT (200 mg) increased alpha brain waves, reduced anxiety, and lowered salivary cortisol.
• Mechanism: increases alpha waves and modulates GABA, serotonin, and dopamine — producing relaxation without sedation. Acute effects same day; cumulative benefits at 2–4 weeks.

Therapeutic dose: 600–1,200 mg/day standardized extract (0.3% hypericin or 2–5% hyperforin)

• Cochrane Review (29 RCTs, 5,489 patients): hypericum extracts superior to placebo (RR 1.28 in larger trials) and similarly effective as SSRIs (RR 1.00). Significantly fewer dropouts due to adverse effects vs SSRIs (OR 0.53).
• 2017 meta-analysis (27 trials, 3,808 patients vs SSRIs): comparable response rate (RR 0.983) and remission rate (RR 1.013), with significantly lower discontinuation (OR 0.587).
• WS 5570 RCT (375 patients, 6 weeks): 900 mg/day significantly superior to placebo on HAM-D in mild-moderate MDD.
• Critical limitation: potent CYP3A4/P-gp inducer — significantly reduces efficacy of oral contraceptives, warfarin, cyclosporine, HIV antiretrovirals. Not safe with SSRIs (serotonin syndrome risk).

Therapeutic dose: 800–1,600 mg/day enteric-coated tablets

• 2024 meta-analysis (23 RCTs, 2,183 patients): SAMe monotherapy significantly superior to placebo (SMD = -0.58). No significant difference from antidepressants (SMD = 0.06).
• Cochrane Review: SAMe superior to placebo and equivalent to TCAs. Global effect size 17–38%.
• SRI augmentation RCT (Papakostas 2010): SAMe 800 mg BID as adjunct showed significantly higher response (36.1% vs 17.6%) and remission (25.8% vs 11.7%) in SSRI non-responders.
• Chemically unstable — quality/storage matters enormously. Enteric-coated tosylate or butanedisulfonate forms required. May trigger mania in bipolar patients.

Therapeutic dose: 288–680 mg/day (3% rosavins + 1% salidroside)

• 2012 systematic review of 11 RCTs found 3/5 mental fatigue studies positive, 2/6 physical performance studies positive. Concluded 'evidence contradictory with methodological flaws.'
• Cropley 2015 (80 mildly anxious adults, 400 mg, 14 days): significant reduction in anxiety, stress, anger, confusion, and depression.
• GAD pilot (10 subjects, 340 mg, 10 weeks): 50% achieved ≥50% HAMA reduction. Promising but extremely small sample.
• Key limitation: high risk of bias and no consistent outcome measures across studies. Optimal form: SHR-5 standardized extract.

Therapeutic dose: 200–400 mg/day elemental magnesium

• 2017 systematic review found suggestive benefit in anxiety-vulnerable samples, though evidence quality was poor.
• 2024 depression meta-analysis of 7 RCTs showed significant benefit (SMD: -0.919, p=0.001).
• Form matters enormously: bisglycinate ~80% bioavailability vs oxide 4–10%. A 400 mg oxide product delivers only ~30–50 mg absorbed magnesium.
• Mechanism: GABA-A receptor agonist + NMDA receptor antagonist; reduces cortisol. Benefits primarily in deficient populations.

Therapeutic dose: 1,000–2,500 mg/day EPA+DHA

• 2024 meta-analysis of 23 RCTs (2,189 participants): each 1g/day produced a moderate anxiety decrease (SMD: -0.70).
• 2021 reactivity RCT (138 adults): 2.5g/day lowered cortisol and IL-6 by 33%.
• Negative finding (2017): 2.2g/day showed NO effect on PSS in chronic work stress — benefits may be limited to anxiety rather than perceived stress.
• Optimal form: EPA-rich triglyceride form. Mechanism: anti-inflammatory + HPA axis modulation. Requires 8–12 weeks for full effect.

Therapeutic dose: 250–1,200 mg/day

• 2022 RCT (100 adults, 250 mg/day, 8 weeks): PSS improved (p=0.003), hair cortisol lower (p=0.025), acute stress buffered (cortisol p=0.001).
• OciBest RCT (150 participants, 1,200 mg/day, 6 weeks): reduced stress symptom scores (p≤0.05).
• 2017 systematic review of 24 studies: all favorable — described as effective adaptogen for modern stresses.
• Mechanism: inhibits CRH receptor-1, reduces cortisol/amylase, enhances serotonin/dopamine. Optimal forms: Holixer or OciBest (standardized).

Therapeutic dose: 28–30 mg/day standardized extract (≥2% safranal, ≥10% crocins)

• 2019 meta-analysis (Nutrition Reviews) of RCTs found large effect sizes for both depression (Hedges' g=0.99) and anxiety (g=0.95) vs placebo.
• 2024 meta-analysis (PubMed 38913392) concluded saffron is comparable to SSRIs for depression and anxiety with significantly fewer adverse events.
• 2021 stress RCT (PMC7882499): saffron delayed peak salivary cortisol during Trier Social Stress Test, demonstrating direct cortisol modulation.
• 2025 RCT: 28 mg/day affron® improved mood and stress scores at 5 weeks in healthy adults.
• Key limitation: noted publication bias in meta-analyses. Nearly all positive trials use branded extracts (affron®). Safe up to 1.5g/day with no severe adverse events reported.

Therapeutic dose: Multi-B ≥3 vitamins at RDA+

• 2019 meta-analysis of 16 trials (2,015 participants): significant benefit for stress (p=0.03). Depression: p=0.07 (trend). Anxiety: p=0.71 (no effect).
• 5 of 8 at-risk population studies found significant benefit — effects more pronounced in stressed or nutritionally at-risk individuals.
• Key distinction: B vitamins reduce perceived stress but do NOT reduce anxiety or depression — important for scoring specificity.
• Optimal form: methylated (methylfolate, methylcobalamin, P-5-P). Requires 4+ weeks for effect. Often confounded by combination products in studies.

Therapeutic dose: 300–800 mg/day (400 mg minimum effective dose)

• 2014 RCT (75 men): 400 mg normalized cortisol response (p=0.043). Critically, 200 mg had NO effect — dose threshold is real.
• 2008 exercise RCT: 600 mg/day reduced cortisol AUC by 35% (p<0.01) and increased testosterone by 37% (p=0.02).
• Consistent cortisol-blunting across studies, but 400 mg minimum dose means many products are underdosed at 100–200 mg.
• Optimal form: soy-derived PS, often combined with phosphatidic acid or omega-3. Mechanism: blunts HPA axis, reduces cortisol and ACTH.

Therapeutic dose: 500–1,500 mg/day curcuminoids (bioavailability-enhanced form)

• 2017 meta-analysis (6 RCTs, 377 patients): curcumin significantly reduced HAM-D scores vs placebo (SMD = -0.344). No adverse events.
• 2025 meta-analysis (15 RCTs, 1,123 patients): nanocurcumin showed strong effects (SMD = -1.30) while standard curcumin did not reach significance (SMD = -0.40).
• Lopresti RCT (56 MDD patients): 1,000 mg/day significantly improved IDS-SR30 from week 4 and reduced IL-1β, TNF-α, and cortisol.
• Standard curcumin has <1% bioavailability. Nanocurcumin/phytosome forms (Meriva, BCM-95) are essential for efficacy.

Therapeutic dose: 2,000–4,000 IU/day D3 (cholecalciferol)

• 2024 dose-response meta-analysis (31 RCTs, 24,189 participants): each 1,000 IU/day D3 reduced depressive symptoms (SMD: -0.32). Effect more pronounced in those with depressive symptoms (SMD: -0.57).
• 2023 meta-analysis (41 RCTs, 53,235 participants): moderate treatment effect (Hedges' g = -0.317). Effective in both MDD and subclinical depression.
• Short-term supplementation (≤8 weeks) produced stronger effects than longer regimens. Trials >52 weeks showed NO significant effect.
• CANMAT guidelines do NOT recommend vitamin D as adjunct for MDD. Effects may be limited to deficient populations.

Therapeutic dose: 15 mg/day L-methylfolate (lower doses not consistently effective)

• 2021 meta-analysis (6 RCTs, 584 participants): adjunctive folate with SSRI/SNRI significantly improved HAM-D scores (MD: -2.16), response rate (RR: 1.36), and remission rate (RR: 1.39).
• Papakostas parallel-sequential RCTs: L-methylfolate 15 mg/day (but NOT 7.5 mg) significantly superior to placebo as SSRI augmentation. NNT ≈ 6.
• WFSBP/CANMAT guidelines: L-methylfolate 15 mg/day provisionally recommended as adjunctive treatment for MDD. Folic acid NOT recommended.
• Most supplements contain 400–1,000 mcg folic acid — a different compound that's 15–37x below effective dose. Form distinction (L-methylfolate vs folic acid) is critical.

Therapeutic dose: 300–3,000 mg/day

• 2021 meta-analysis found significant anxiety reduction (SMD: -0.98, p=0.003) and depression reduction (SMD: -0.47, p=0.0005), but with high heterogeneity.
• Acute RCT (600 mg single dose) ameliorated negative mood and increased calmness.
• 2023 phytosome RCT (400 mg/day, 3 weeks): phospholipid extract improved anxiety, stress, and wellbeing (all p<0.001).
• Key limitation: dosing varies 10x across studies (300–3,000 mg). Optimal forms: Cyracos or phospholipid-based (Relissa).

Therapeutic dose: 200–1,600 mg/day

• 2020 review of 9 RCTs: majority reported reduced anxiety with no adverse effects.
• GAD trial (36 patients): as effective as oxazepam 30 mg/day with less cognitive impairment.
• 2024 RCT (65 participants, 30 days): reduced PSS and improved quality of life and insomnia scores.
• Successfully used in benzodiazepine tapering at 200–600 mg/day (approved in Italy as Tractana). Key limitation: mostly 1–30 day durations with small samples.

Therapeutic dose: 250 mg 2–3x/day (500–750 mg/day total)

• Talbott 2013 (63 adults, 42 days, 750 mg/day): reduced salivary cortisol by 18% (p<0.05) and improved POMS vigor and fatigue subscales. Manufacturer-funded.
• Kalman 2008 (56 adults, 4 weeks, 500 mg/day): NO significant cortisol reduction. Reduced weight gain associated with stress eating. Manufacturer-funded.
• Conflicting cortisol results across the two available RCTs — one positive, one null. Both had small samples and industry funding.
• Mechanism: honokiol (magnolia) is a GABAergic anxiolytic; berberine (phellodendron) modulates cortisol. GABAergic mechanism is well-characterized but clinical translation is limited.

Therapeutic dose: 100–300 mg/day

• 2020 systematic review of 14 placebo-controlled trials found mixed results for oral GABA on stress and sleep, with high methodological variability.
• GABA/5-HTP combination study: reduced sleep onset (32→19 min, p=0.01) and increased duration (5→6.8 hrs, p=0.01).
• Fundamental question unresolved: whether supplemental GABA crosses the blood-brain barrier is debated. May act via the enteric nervous system (gut-brain axis).
• PharmaGABA (fermented, natural L-form) may have better efficacy than synthetic GABA. Acute effects within 30–60 minutes.

Therapeutic dose: Strain-specific; 1–10B CFU/day

• 2024 meta-analysis of 23 RCTs (1,401 patients) found moderate anxiety reduction (SMD: -0.59) in clinical populations.
• L. plantarum DR7 RCT (111 adults, 12 weeks): reduced anxiety (p=0.001), stress (p=0.024), and lowered cortisol.
• Inconsistencies: L. rhamnosus failed to prevent cortisol elevation. B. longum at 16 weeks showed no effect.
• 2024 review concluded 'not yet strong enough evidence to support inclusion in treatment guidelines.' Highly strain-dependent with many null results.

Therapeutic dose: 150–300 mg/day

• Kim 2007 DB-RCT (63 women, 150 mg/day, 30 days, crossover): reduced stress symptoms across digestive (p<0.01), cardiovascular (p<0.05), intellectual (p<0.01), emotional (p<0.05), and social (p<0.05) domains.
• Messaoudi 2005 DB-RCT (healthy volunteers, 200 mg acute ×3 doses): significant cortisol reduction under combined stress tests (p<0.05) and lower blood pressure changes vs placebo.
• CERTAIN 2022 (100 acne patients, 150 mg/day, 12 weeks): cortisol −4.75 µg/dL (p<0.001), PSS and HAM-A improved (p<0.001). However, open-label design substantially weakens findings.
• Mechanism: contains alpha-casozepine, a decapeptide from bovine alpha-s1 casein that binds GABA-A receptors with benzodiazepine-like anxiolytic action without dependence risk. No meta-analysis exists; most studies involve manufacturer Ingredia.

Therapeutic dose: 8–25 mg/day

• 2023 meta-analysis of 4 studies (117 participants) concluded 'no clinical difference' between Sceletium tortuosum and placebo for anxiety. Stated it is 'not possible to guarantee Sceletium tortuosum affects anxiety.'
• Reay 2020 RCT (20 healthy volunteers, single 25 mg dose): Study 1 null; Study 2 showed lower pre-stress anxiety. Authors called it 'first tentative behavioral evidence.'
• Terburg 2013 fMRI (16 participants, single 25 mg dose): attenuated amygdala reactivity to fearful faces — mechanistic/neuroimaging only, not clinical stress outcomes.
• Mechanism: dual PDE4 inhibitor + 5-HT reuptake inhibitor — pharmacology is well-characterized. No chronic supplementation RCTs measuring stress/anxiety as primary endpoints. No cortisol data in any study.

Therapeutic dose: 150–300 mg/day

• Direct serotonin precursor with strong theoretical rationale, but modern clinical evidence is remarkably thin. 2012 Cochrane review found insufficient evidence.
• One of the most popular mood supplements, yet its evidence base is among the weakest. Should NOT be combined with SSRIs/SNRIs (serotonin syndrome risk).

Therapeutic dose: 25–50 mg/day elemental zinc

• Multiple meta-analyses show lower serum zinc in depressed individuals. 2013 meta-analysis of adjunctive zinc (25 mg/day) with antidepressants showed significant improvement.
• Evidence for standalone mood benefit is limited. Primarily an adjunctive cofactor role.